We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-11.1%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$55.3M
AUM Growth
-$12.2M
Cap. Flow
-$3.77M
Cap. Flow %
-6.81%
Top 10 Hldgs %
62.56%
Holding
65
New
2
Increased
18
Reduced
1
Closed
10
Avg Time Held Equity + Options
2.1 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
1.3 years
Avg Time Held Equity only
2.1 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.5 years

Top Buys

Rank Stock Value
1
FBIO icon
Fortress Biotech
FBIO
+$595K
2
AMRN icon
Amarin Corp
AMRN
+$297K
3
UTHR icon
United Therapeutics
UTHR
+$282K
4
ALKS icon
Alkermes
ALKS
+$253K
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$64.5K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$868K
2
SRPT icon
Sarepta Therapeutics
SRPT
+$813K
3
BLUE icon
bluebird bio
BLUE
+$743K
4
INSM icon
Insmed
INSM
+$690K
5
PCRX icon
Pacira BioSciences
PCRX
+$489K

Sector Composition

Rank Sector Weight
1 Healthcare 56.66%
2 Miscellaneous 43.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IBB icon
1
iShares Biotechnology ETF
IBB
$10.6B
$12.4M 22.48%
125,000
– –
2018 Q4
3 quarters
IBB icon
2
CALL
iShares Biotechnology ETF
IBB
$10.6B
$8.46M 15.28%
85,000
– –
2018 Q4
3 quarters
LABU icon
3
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$569M
$3.09M 5.58%
4,993
+71
+1% +$59K
2018 Q4
3 quarters
MTD icon
4
Mettler-Toledo International
MTD
$32.6B
$2.28M 4.12%
3,235
– –
2014 Q4
19 quarters
BMY icon
5
Bristol-Myers Squibb
BMY
$120B
$1.67M 3.02%
33,000
– –
2019 Q1
2 quarters
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
$1.54M 2.78%
18,020
+119
+0.7% +$8.72K
2014 Q4
19 quarters
ILMN icon
7
Illumina
ILMN
$39.7B
$1.44M 2.6%
4,853
+22
+0.5% +$6.48K
2014 Q4
19 quarters
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$127B
$1.4M 2.54%
8,279
+86
+1% +$15.2K
2014 Q4
19 quarters
IONS icon
9
Ionis Pharmaceuticals
IONS
$7.38B
$1.21M 2.18%
20,124
– –
2014 Q4
19 quarters
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$31.2B
$1.1M 1.99%
13,684
+333
+2% +$26.3K
2014 Q4
19 quarters
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$973K 1.76%
9,933
+6
+0.1% +$676
2014 Q4
19 quarters
QGEN icon
12
Qiagen
QGEN
$9.6B
$951K 1.72%
27,215
– –
2017 Q1
10 quarters
ONCE
13
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$941K 1.7%
9,699
– –
2019 Q1
2 quarters
FBIO icon
14
Fortress Biotech
FBIO
$62.4M
$865K 1.56%
40,903
+25,301
+162% +$595K
2018 Q3
4 quarters
PRQR icon
15
ProQR Therapeutics
PRQR
$185M
$798K 1.44%
138,461
– –
2017 Q4
7 quarters
INCY icon
16
Incyte
INCY
$23B
$791K 1.43%
10,659
+46
+0.4% +$3.72K
2014 Q4
19 quarters
EXAS icon
17
DELISTED
Exact Sciences
EXAS
$771K 1.39%
8,534
– –
2019 Q1
2 quarters
REGN icon
18
Regeneron Pharmaceuticals
REGN
$80.5B
$677K 1.22%
2,439
+218
+10% +$64.5K
2014 Q4
19 quarters
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$10.6B
$654K 1.18%
9,700
+300
+3% +$23.1K
2014 Q4
19 quarters
DCPH icon
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$632K 1.14%
18,631
– –
2019 Q1
2 quarters
ASND icon
21
Ascendis Pharma A/S
ASND
$15.1B
$596K 1.08%
6,190
– –
2019 Q1
2 quarters
QURE icon
22
uniQure
QURE
$1.54B
$560K 1.01%
14,215
– –
2019 Q1
2 quarters
CELG
23
DELISTED
Celgene Corp
CELG
$559K 1.01%
5,625
– –
2014 Q4
19 quarters
CRSP icon
24
CRISPR Therapeutics
CRSP
$4.84B
$542K 0.98%
13,214
– –
2019 Q1
2 quarters
EPZM
25
DELISTED
Epizyme, Inc
EPZM
$520K 0.94%
50,378
– –
2019 Q1
2 quarters
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2019 Portfolio in Review

As of Q3 2019, Opus Point Partners Management held 65 positions worth $55.3M, down 18% from $67.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opus Point Partners Management withdrew a net $3.77M in Q3 2019, closing 10 positions and reducing 1 holding. Its most notable exit was Immunomedics Inc, an estimated $868K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 59% a quarter earlier, followed by Miscellaneous.

Against the trend, Opus Point Partners Management opened a new position in United Therapeutics worth $279K.

  • Opus Point Partners Management's largest Q3 2019 buy was United Therapeutics: 3,498 shares worth $279K.
  • Opus Point Partners Management added most to Fortress Biotech in Q3 2019, an estimated $595K increase.
  • Opus Point Partners Management's biggest Q3 2019 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $131K.
  • Opus Point Partners Management fully exited Immunomedics Inc in Q3 2019, selling an estimated $868K.
  • Opus Point Partners Management's ten largest holdings make up 63% of its $55.3M portfolio in Q3 2019.
  • Opus Point Partners Management opened 2 new positions and closed 10 in Q3 2019.
  • Opus Point Partners Management's portfolio value fell 18% quarter-over-quarter to $55.3M.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.